200 related articles for article (PubMed ID: 11070113)
21. Reversal of graft steatosis after liver transplantation: prospective study.
Li J; Liu B; Yan LN; Zuo YX; Li B; Zeng Y; Zhang SF; Li FG
Transplant Proc; 2009 Nov; 41(9):3560-3. PubMed ID: 19917344
[TBL] [Abstract][Full Text] [Related]
22. Effect of graft steatosis on liver function and organ survival after liver transplantation.
Angele MK; Rentsch M; Hartl WH; Wittmann B; Graeb C; Jauch KW; Loehe F
Am J Surg; 2008 Feb; 195(2):214-20. PubMed ID: 18154767
[TBL] [Abstract][Full Text] [Related]
23. Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests.
Abraham SC; Poterucha JJ; Rosen CB; Demetris AJ; Krasinskas AM
Am J Surg Pathol; 2008 Jul; 32(7):965-73. PubMed ID: 18460980
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of frozen-section analysis in the histological assessment of steatosis before liver transplantation.
Fiorentino M; Vasuri F; Ravaioli M; Ridolfi L; Grigioni WF; Pinna AD; D'Errico-Grigioni A
Liver Transpl; 2009 Dec; 15(12):1821-5. PubMed ID: 19938115
[TBL] [Abstract][Full Text] [Related]
25. The effect of donor body mass index on primary graft nonfunction, retransplantation rate, and early graft and patient survival after liver transplantation.
Yoo HY; Molmenti E; Thuluvath PJ
Liver Transpl; 2003 Jan; 9(1):72-8. PubMed ID: 12514776
[TBL] [Abstract][Full Text] [Related]
26. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index.
de Graaf EL; Kench J; Dilworth P; Shackel NA; Strasser SI; Joseph D; Pleass H; Crawford M; McCaughan GW; Verran DJ
J Gastroenterol Hepatol; 2012 Mar; 27(3):540-6. PubMed ID: 21777274
[TBL] [Abstract][Full Text] [Related]
27. Nonalcoholic steatohepatitis in donors for living donor liver transplantation.
Yamamoto K; Takada Y; Fujimoto Y; Haga H; Oike F; Kobayashi N; Tanaka K
Transplantation; 2007 Feb; 83(3):257-62. PubMed ID: 17297396
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and clinical associations of posttransplant fatty liver disease.
Lim LG; Cheng CL; Wee A; Lim SG; Lee YM; Sutedja DS; Da Costa M; Prabhakaran K; Wai CT
Liver Int; 2007 Feb; 27(1):76-80. PubMed ID: 17241384
[TBL] [Abstract][Full Text] [Related]
29. Absence of impact of donor hepatic steatosis and posttransplantation lamivudine resistance in a patient with chronic hepatitis B.
Chan HL; Chui AK; Rao AR; Hui AY; Wong J; Lau WY
Transplant Proc; 2004 Oct; 36(8):2309-10. PubMed ID: 15561232
[TBL] [Abstract][Full Text] [Related]
30. Frozen-section diagnosis in donor livers: error rate estimation of steatosis degree.
D'Alessandro E; Calabrese F; Gringeri E; Valente M
Transplant Proc; 2010; 42(6):2226-8. PubMed ID: 20692450
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors for pure steatosis in alcoholic patients.
Naveau S; Thaury J; Barri-Ova N; Balian A; Dauvois B; Njiké-Nakseu M; Prévot S; Agostini H; Perlemuter G
Alcohol Clin Exp Res; 2009 Jun; 33(6):1104-10. PubMed ID: 19382900
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients.
Valva P; De Matteo E; Galoppo M; Pedreira A; Giacove G; Lezama C; Marco I; Galoppo MC; Preciado MV
Hum Pathol; 2008 Dec; 39(12):1816-22. PubMed ID: 18715620
[TBL] [Abstract][Full Text] [Related]
33. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol.
Monto A; Alonzo J; Watson JJ; Grunfeld C; Wright TL
Hepatology; 2002 Sep; 36(3):729-36. PubMed ID: 12198667
[TBL] [Abstract][Full Text] [Related]
34. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis.
Berenguer M; Prieto M; Palau A; Rayón JM; Carrasco D; Juan FS; López-Labrador FX; Moreno R; Mir J; Berenguer J
Liver Transpl; 2003 Mar; 9(3):228-35. PubMed ID: 12619018
[TBL] [Abstract][Full Text] [Related]
35. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
[TBL] [Abstract][Full Text] [Related]
36. Recurrent familial hypobetalipoproteinemia-induced nonalcoholic fatty liver disease after living donor liver transplantation.
Harada N; Soejima Y; Taketomi A; Yoshizumi T; Uchiyama H; Ikegami T; Saibara T; Nishizaki T; Maehara Y
Liver Transpl; 2009 Jul; 15(7):806-9. PubMed ID: 19562718
[TBL] [Abstract][Full Text] [Related]
37. Successful use of extended criteria donor grafts with low to moderate steatosis in patients with model for end-stage liver disease scores below 27.
Avolio AW; Frongillo F; Nicolotti N; Mulè A; Vennarecci G; De Simone P; Agnes S
Transplant Proc; 2009; 41(1):208-12. PubMed ID: 19249515
[TBL] [Abstract][Full Text] [Related]
38. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors.
Tran TT; Changsri C; Shackleton CR; Poordad FF; Nissen NN; Colquhoun S; Geller SA; Vierling JM; Martin P
J Gastroenterol Hepatol; 2006 Feb; 21(2):381-3. PubMed ID: 16509862
[TBL] [Abstract][Full Text] [Related]
39. Hepatic steatosis in liver transplant donors: rare phenomenon or common feature of donor population?
Hałoń A; Patrzałek D; Rabczyński J
Transplant Proc; 2006; 38(1):193-5. PubMed ID: 16504700
[TBL] [Abstract][Full Text] [Related]
40. De novo nonalcoholic fatty liver disease after liver transplantation.
Seo S; Maganti K; Khehra M; Ramsamooj R; Tsodikov A; Bowlus C; McVicar J; Zern M; Torok N
Liver Transpl; 2007 Jun; 13(6):844-7. PubMed ID: 17029282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]